Cardiovascular Drugs and Therapy

Cardiovascular Drugs and Therapy is dedicated to the development of cardiovascular drug, device, and cell therapy from bench to bedside. The journals takes a fresh and energetic look at advances in this dynamic field.

Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focuses on developments that include: hyperlipidemia, diabetes and other cardiometabolic conditions, atherosclerosis, ischemic syndromes, heart failure, cardiomyopathies, valvular heart disease, and arrhythmias. These include mechanisms of action and signaling pathways, their potential for new drug development, novel indications for older drugs, genetic approach to treatment, and new directions in device and cell therapy, interventional and structural heart disease, and cardiac and vascular surgery, as well as their guideline-based utilization in real-world patient populations.
• Authoritative source for researchers and investigators aiming for breakthrough research as well as cardiologists seeking to best serve their patients.
• Focuses on developments in treatment of various cardiovascular conditions.
• Listed in Web of Science and PubMed/Medline among other abstracting and indexing services.
• International readership: North America, Asia, Europe, Middle East and South America
• Efficient handling with 18 days between submission and first decision, and 17 days between acceptance and online publication.
• High usage and wide distribution with a global readership.